Farmakoterapi Pasien Hiperkolesterolemia Familial: Suatu Tinjauan Narasi
Abstract
Hiperkolesterolemia familial (FH) merupakan kelainan autosomal dominan yang ditandai dengan kadar low-density lipoprotein kolesterol (LDL-C) yang tinggi pada plasma. Bahaya risiko kejadian kardiovaskular dan tingginya angka prevalensi menjadikan hiperkolesterolemia familial beban penyakit yang harus segera ditangani. Tujuan penulisan artikel ini adalah membahas manajemen terapi farmakologis untuk menurunkan kadar LDL-C dalam plasma. Metode artikel ini merupakan tinjauan pustaka dengan penelusuran elektronik komprehensif dilakukan menggunakan PubMed dan Google Scholar. Pencarian terbatas pada bahasa Inggris dan bahasa Indonesia. Didapatkan 51 literatur yang sesuai dengan topik dan dianalisa. Terdapat banyak terapi dislipidemia yang tersedia dengan berbagai target terapi. Statin tetap menjadi yang paling popular dan pilihan utama pada rekomendasi-rekomendasi yang ada. Meskipun begitu, pada pasien intoleransi statin, terdapat banyak pula pilihan pengobatan yang dinilai cukup efektif untuk menurunkan kadar LDL-C, meskipun banyak juga diantaranya masih membutuhkan penelitian lebih lanjut dalam hal keamanan jangka panjang. Kesimpulannya statin tetap menjadi lini pertama dalam pengobatan hiperkolesterolemia familial, jika target tidak tercapai dapat dikombinasikan dengan obat penurun kolesterol lainnya.
Full text article
Generated from XML file
References
Adhyaru, B. B., & Jacobson, T. A. (2013). Safety and efficacy of statin therapy. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-018-0098-5
Akoumianakis, I., Zvintzou, E., Kypreos, K., & Filippatos, T. D. (2021). ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports, 23(5). https://doi.org/10.1007/s11883-021-00914-7
Avis, H. J., Hutten, B. A., Gagné, C., Langslet, G., McCrindle, B. W., Wiegman, A., … Stein, E. A. (2010). Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 55(11), 1121–1126. https://doi.org/10.1016/j.jacc.2009.10.042
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018). Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, plasebo-controlled study. Atherosclerosis, 277, 195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002
Ballantyne, C. M., Bays, H., Catapano, A. L., Goldberg, A., Ray, K. K., & Saseen, J. J. (2021). Role of Bempedoic Acid in Clinical Practice. Cardiovascular Drugs and Therapy, 35(4), 853–864. https://doi.org/10.1007/s10557-021-07147-5
Bateman, B. T., Hernandez-Diaz, S., Fischer, M. A., Seely, E. W., Ecker, J. L., Franklin, J. M., … Huybrechts, K. F. (2015). Statins and congenital malformations: cohort study. BMJ (Clinical Research Ed.), 350, h1035. https://doi.org/10.1136/bmj.h1035
Benito-Vicente, A., Uribe, K. B., Jebari, S., Galicia-Garcia, U., Ostolaza, H., & Martin, C. (2018). Familial hypercholesterolemia: The most frequent cholesterol metabolism disorder caused disease. International Journal of Molecular Sciences, 19(11). https://doi.org/10.3390/ijms19113426
Bile Acid Resins or Sequestrants. (2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, (Md), 2–5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/31643664
Blom, D. J., Harada-Shiba, M., Rubba, P., Gaudet, D., Kastelein, J. J. P., Charng, M. J., … Rosenson, R. S. (2020). Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. Journal of the American College of Cardiology, 76(2), 131–142. https://doi.org/10.1016/j.jacc.2020.05.027
Brown, M. S., & Goldstein, J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science, 232(4746), 34–47. https://doi.org/10.1126/science.3513311
Constatine, M. M., & Cleary, K. (2013). Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women. Obstet Gynecol, 23(1), 1–7. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
Costantine, M. M., Cleary, K., Hebert, M. F., Ahmed, M. S., Brown, L. M., Ren, Z., … Hankins, G. (2016). Safety and Pharmacokinetics of Pravastatin Used for the Prevention of Preeclampsia in High-Risk Pregnant Women: A Pilot Randomized Controlled Trial. Physiology & Behavior, 176(3), 139–148. https://doi.org/10.1016/j.ajog.2015.12.038.Safety
Fiorentino, R., & Chiarelli, F. (2021). Treatment of dyslipidaemia in children. Biomedicines, 9(9). https://doi.org/10.3390/biomedicines9091078
Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019). Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs, 79(7), 751–766. https://doi.org/10.1007/s40265-019-01114-z
Gencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., … Sabatine, M. S. (2021). Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials, 396(10263), 1637–1643. https://doi.org/10.1016/S0140-6736(20)32332-1.Efficacy
Giugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., … Braunwald, E. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137(15), 1571–1582. https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., … Tsimikas, S. (2017). Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides . New England Journal of Medicine, 377(3), 222–232. https://doi.org/10.1056/nejmoa1701329
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., … Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), 3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002
Harada-Shiba, M., Arai, H., Ishigaki, Y., Ishibashi, S., Okamura, T., Ogura, M., … Yokote, K. (2018). Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. Journal of Atherosclerosis and Thrombosis, 25(8), 751–770. https://doi.org/10.5551/jat.CR003
Khoury, E., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2019). Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert Opinion on Drug Safety, 18(5), 403–414. https://doi.org/10.1080/14740338.2019.1602606
Lamb, Y. N. (2020). Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. American Journal of Cardiovascular Drugs, 20(4), 381–392. https://doi.org/10.1007/s40256-020-00421-1
Li, Y. H., Ueng, K. C., Jeng, J. S., Charng, M. J., Lin, T. H., Chien, K. L., … Yeh, H. I. (2017). 2017 Taiwan lipid guidelines for high risk patients. Journal of the Formosan Medical Association, 116(4), 217–248. https://doi.org/10.1016/j.jfma.2016.11.013
Ma, Y. Bin, Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019). Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 20(8), 917–928. https://doi.org/10.1080/14656566.2019.1594776
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., … Patel, R. S. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
Maliachova, O., & Stabouli, S. (2018). Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment. Current Pharmaceutical Design, 24(31), 3672–3677. https://doi.org/10.2174/1381612824666181010145807
Markham, A. (2021). Evinacumab: First Approval. Drugs, (0123456789). https://doi.org/10.1007/s40265-021-01516-y
McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M., & Duell, P. B. (2019). Diagnosis and treatment of heterozygous familial hypercholesterolemia. Journal of the American Heart Association, 8(24), 1–16. https://doi.org/10.1161/JAHA.119.013225
Mihalopoulos, N. L., Stipelman, C., Hemond, J., Brown, L. L., & Young, P. C. (2018). Universal Lipid Screening in 9- to 11-Year-Olds Before and After 2011 Guidelines. Academic Pediatrics, 18(2), 196–199. https://doi.org/10.1016/j.acap.2017.11.006
Miname, M. H., & Santos, R. D. (2019). Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Progress in Cardiovascular Diseases, 62(5), 414–422. https://doi.org/10.1016/j.pcad.2019.10.003
Mytilinaiou, M., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018). Familial hypercholesterolemia: New horizons for diagnosis and effective management. Frontiers in Pharmacology, 9(JUN). https://doi.org/10.3389/fphar.2018.00707
Nohara, A., Tada, H., Ogura, M., Okazaki, S., Ono, K., Shimano, H., … Harada-Shiba, M. (2021). Homozygous familial hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 28(7), 665–678. https://doi.org/10.5551/jat.RV17050
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., … Tybjærg-Hansen, A. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. European Heart Journal, 34(45), 3478–3490. https://doi.org/10.1093/eurheartj/eht273
Nurmohamed, N. S., Navar, A. M., & Kastelein, J. J. P. (2021). New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. Journal of the American College of Cardiology, 77(12), 1564–1575. https://doi.org/10.1016/j.jacc.2020.11.079
Ogura, M. (2018). PCSK9 inhibition in the management of familial hypercholesterolemia. Journal of Cardiology, 71(1), 1–7. https://doi.org/10.1016/j.jjcc.2017.07.002
Padmanabhan, A., Connelly-Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., … Schwartz, G. E. J. (2019). Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 34(3), 171–354. https://doi.org/10.1002/jca.21705
Pang, J., Chan, D. C., & Watts, G. F. (2020). The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Current Atherosclerosis Reports, 22(11). https://doi.org/10.1007/s11883-020-00884-2
Pasta, A., Cremonini, A. L., Pisciotta, L., Buscaglia, A., Barra, F., Ferrero, S., … Pcsk, R. (2020). PCSK9 inhibitors for treating hypercholesterolemia. Expert Opinion on Pharmacotherapy, 00(00), 1–11. https://doi.org/10.1080/14656566.2019.1702970
Pevzner. (2017). Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. Physiology & Behavior, 176(3), 139–148. https://doi.org/10.1056/NEJMoa1612790.Genetic
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021). Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Current Atherosclerosis Reports, 23(12). https://doi.org/10.1007/s11883-021-00972-x
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., … Yancopoulos, G. D. (2020). Evinacumab for Homozygous Familial Hypercholesterolemia. The New England Jpurnal of Medicine, 711–720. https://doi.org/10.1056/NEJMoa2004215
Rader, D. J., & Kastelein, J. J. P. (2014). Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation, 129(9), 1022–1032. https://doi.org/10.1161/CIRCULATIONAHA.113.001292
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., … Ballantyne, C. M. (2019). Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine, 380(11), 1022–1032. https://doi.org/10.1056/nejmoa1803917
Reeskamp, L. F., Kastelein, J. J. P., Moriarty, P. M., Duell, P. B., Catapano, A. L., Santos, R. D., & Ballantyne, C. M. (2019). Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 280, 109–117. https://doi.org/10.1016/j.atherosclerosis.2018.11.017
Roeters van Lennep, J. E., Visseren, F. L. J., & Jira, P. E. (2015). [Familial hypercholesterolemia: why screening, counselling and treatment should be integrated]. Nederlands tijdschrift voor geneeskunde, 159, A8875.
Santos, R. D., Gidding, S. S., Hegele, R. A., Cuchel, M. A., Barter, P. J., Watts, G. F., … Yamashita, S. (2016). Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. The Lancet Diabetes and Endocrinology, 4(10), 850–861. https://doi.org/10.1016/S2213-8587(16)30041-9
Sbrana, F., Dal Pino, B., Bigazzi, F., Ripoli, A., Passino, C., Gabutti, A., … Sampietro, T. (2017). Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? European Journal of Preventive Cardiology, 24(14), 1528–1531. https://doi.org/10.1177/2047487317712419
Singh, S., & Bittner, V. (2015). Familial hypercholesterolemia--epidemiology, diagnosis, and screening. Current Atherosclerosis Reports, 17(2), 482. https://doi.org/10.1007/s11883-014-0482-5
Strilchuk, L., Tocci, G., Fogacci, F., & Cicero, A. F. G. (2020). An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 21(5), 531–539. https://doi.org/10.1080/14656566.2020.1714028
Sturm, A. C., Knowles, J. W., Gidding, S. S., Ahmad, Z. S., Ahmed, C. D., Ballantyne, C. M., … Rader, D. J. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. Journal of the American College of Cardiology, 72(6), 662–680. https://doi.org/10.1016/j.jacc.2018.05.044
Turgeon, R. D., Barry, A. R., & Pearson, G. J. (2016). Familial hypercholesterolemia review of diagnosis, screening, and treatment. Canadian Family Physician, 62(1), 32–37.
Youngblom, E., Pariani, M., & Knowles, J. W. (2016). Familial Hypercholesterolemia. GeneReviews® [Internet], 1–28. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK174884/
Akoumianakis, I., Zvintzou, E., Kypreos, K., & Filippatos, T. D. (2021). ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports, 23(5). https://doi.org/10.1007/s11883-021-00914-7
Avis, H. J., Hutten, B. A., Gagné, C., Langslet, G., McCrindle, B. W., Wiegman, A., … Stein, E. A. (2010). Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 55(11), 1121–1126. https://doi.org/10.1016/j.jacc.2009.10.042
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018). Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, plasebo-controlled study. Atherosclerosis, 277, 195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002
Ballantyne, C. M., Bays, H., Catapano, A. L., Goldberg, A., Ray, K. K., & Saseen, J. J. (2021). Role of Bempedoic Acid in Clinical Practice. Cardiovascular Drugs and Therapy, 35(4), 853–864. https://doi.org/10.1007/s10557-021-07147-5
Bateman, B. T., Hernandez-Diaz, S., Fischer, M. A., Seely, E. W., Ecker, J. L., Franklin, J. M., … Huybrechts, K. F. (2015). Statins and congenital malformations: cohort study. BMJ (Clinical Research Ed.), 350, h1035. https://doi.org/10.1136/bmj.h1035
Benito-Vicente, A., Uribe, K. B., Jebari, S., Galicia-Garcia, U., Ostolaza, H., & Martin, C. (2018). Familial hypercholesterolemia: The most frequent cholesterol metabolism disorder caused disease. International Journal of Molecular Sciences, 19(11). https://doi.org/10.3390/ijms19113426
Bile Acid Resins or Sequestrants. (2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, (Md), 2–5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/31643664
Blom, D. J., Harada-Shiba, M., Rubba, P., Gaudet, D., Kastelein, J. J. P., Charng, M. J., … Rosenson, R. S. (2020). Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. Journal of the American College of Cardiology, 76(2), 131–142. https://doi.org/10.1016/j.jacc.2020.05.027
Brown, M. S., & Goldstein, J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science, 232(4746), 34–47. https://doi.org/10.1126/science.3513311
Constatine, M. M., & Cleary, K. (2013). Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women. Obstet Gynecol, 23(1), 1–7. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
Costantine, M. M., Cleary, K., Hebert, M. F., Ahmed, M. S., Brown, L. M., Ren, Z., … Hankins, G. (2016). Safety and Pharmacokinetics of Pravastatin Used for the Prevention of Preeclampsia in High-Risk Pregnant Women: A Pilot Randomized Controlled Trial. Physiology & Behavior, 176(3), 139–148. https://doi.org/10.1016/j.ajog.2015.12.038.Safety
Fiorentino, R., & Chiarelli, F. (2021). Treatment of dyslipidaemia in children. Biomedicines, 9(9). https://doi.org/10.3390/biomedicines9091078
Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019). Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs, 79(7), 751–766. https://doi.org/10.1007/s40265-019-01114-z
Gencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., … Sabatine, M. S. (2021). Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials, 396(10263), 1637–1643. https://doi.org/10.1016/S0140-6736(20)32332-1.Efficacy
Giugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., … Braunwald, E. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137(15), 1571–1582. https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., … Tsimikas, S. (2017). Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides . New England Journal of Medicine, 377(3), 222–232. https://doi.org/10.1056/nejmoa1701329
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., … Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), 3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002
Harada-Shiba, M., Arai, H., Ishigaki, Y., Ishibashi, S., Okamura, T., Ogura, M., … Yokote, K. (2018). Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. Journal of Atherosclerosis and Thrombosis, 25(8), 751–770. https://doi.org/10.5551/jat.CR003
Khoury, E., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2019). Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert Opinion on Drug Safety, 18(5), 403–414. https://doi.org/10.1080/14740338.2019.1602606
Lamb, Y. N. (2020). Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. American Journal of Cardiovascular Drugs, 20(4), 381–392. https://doi.org/10.1007/s40256-020-00421-1
Li, Y. H., Ueng, K. C., Jeng, J. S., Charng, M. J., Lin, T. H., Chien, K. L., … Yeh, H. I. (2017). 2017 Taiwan lipid guidelines for high risk patients. Journal of the Formosan Medical Association, 116(4), 217–248. https://doi.org/10.1016/j.jfma.2016.11.013
Ma, Y. Bin, Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019). Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 20(8), 917–928. https://doi.org/10.1080/14656566.2019.1594776
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., … Patel, R. S. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
Maliachova, O., & Stabouli, S. (2018). Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment. Current Pharmaceutical Design, 24(31), 3672–3677. https://doi.org/10.2174/1381612824666181010145807
Markham, A. (2021). Evinacumab: First Approval. Drugs, (0123456789). https://doi.org/10.1007/s40265-021-01516-y
McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M., & Duell, P. B. (2019). Diagnosis and treatment of heterozygous familial hypercholesterolemia. Journal of the American Heart Association, 8(24), 1–16. https://doi.org/10.1161/JAHA.119.013225
Mihalopoulos, N. L., Stipelman, C., Hemond, J., Brown, L. L., & Young, P. C. (2018). Universal Lipid Screening in 9- to 11-Year-Olds Before and After 2011 Guidelines. Academic Pediatrics, 18(2), 196–199. https://doi.org/10.1016/j.acap.2017.11.006
Miname, M. H., & Santos, R. D. (2019). Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Progress in Cardiovascular Diseases, 62(5), 414–422. https://doi.org/10.1016/j.pcad.2019.10.003
Mytilinaiou, M., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018). Familial hypercholesterolemia: New horizons for diagnosis and effective management. Frontiers in Pharmacology, 9(JUN). https://doi.org/10.3389/fphar.2018.00707
Nohara, A., Tada, H., Ogura, M., Okazaki, S., Ono, K., Shimano, H., … Harada-Shiba, M. (2021). Homozygous familial hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 28(7), 665–678. https://doi.org/10.5551/jat.RV17050
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., … Tybjærg-Hansen, A. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. European Heart Journal, 34(45), 3478–3490. https://doi.org/10.1093/eurheartj/eht273
Nurmohamed, N. S., Navar, A. M., & Kastelein, J. J. P. (2021). New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. Journal of the American College of Cardiology, 77(12), 1564–1575. https://doi.org/10.1016/j.jacc.2020.11.079
Ogura, M. (2018). PCSK9 inhibition in the management of familial hypercholesterolemia. Journal of Cardiology, 71(1), 1–7. https://doi.org/10.1016/j.jjcc.2017.07.002
Padmanabhan, A., Connelly-Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., … Schwartz, G. E. J. (2019). Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 34(3), 171–354. https://doi.org/10.1002/jca.21705
Pang, J., Chan, D. C., & Watts, G. F. (2020). The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Current Atherosclerosis Reports, 22(11). https://doi.org/10.1007/s11883-020-00884-2
Pasta, A., Cremonini, A. L., Pisciotta, L., Buscaglia, A., Barra, F., Ferrero, S., … Pcsk, R. (2020). PCSK9 inhibitors for treating hypercholesterolemia. Expert Opinion on Pharmacotherapy, 00(00), 1–11. https://doi.org/10.1080/14656566.2019.1702970
Pevzner. (2017). Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. Physiology & Behavior, 176(3), 139–148. https://doi.org/10.1056/NEJMoa1612790.Genetic
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021). Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Current Atherosclerosis Reports, 23(12). https://doi.org/10.1007/s11883-021-00972-x
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., … Yancopoulos, G. D. (2020). Evinacumab for Homozygous Familial Hypercholesterolemia. The New England Jpurnal of Medicine, 711–720. https://doi.org/10.1056/NEJMoa2004215
Rader, D. J., & Kastelein, J. J. P. (2014). Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation, 129(9), 1022–1032. https://doi.org/10.1161/CIRCULATIONAHA.113.001292
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., … Ballantyne, C. M. (2019). Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine, 380(11), 1022–1032. https://doi.org/10.1056/nejmoa1803917
Reeskamp, L. F., Kastelein, J. J. P., Moriarty, P. M., Duell, P. B., Catapano, A. L., Santos, R. D., & Ballantyne, C. M. (2019). Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 280, 109–117. https://doi.org/10.1016/j.atherosclerosis.2018.11.017
Roeters van Lennep, J. E., Visseren, F. L. J., & Jira, P. E. (2015). [Familial hypercholesterolemia: why screening, counselling and treatment should be integrated]. Nederlands tijdschrift voor geneeskunde, 159, A8875.
Santos, R. D., Gidding, S. S., Hegele, R. A., Cuchel, M. A., Barter, P. J., Watts, G. F., … Yamashita, S. (2016). Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. The Lancet Diabetes and Endocrinology, 4(10), 850–861. https://doi.org/10.1016/S2213-8587(16)30041-9
Sbrana, F., Dal Pino, B., Bigazzi, F., Ripoli, A., Passino, C., Gabutti, A., … Sampietro, T. (2017). Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? European Journal of Preventive Cardiology, 24(14), 1528–1531. https://doi.org/10.1177/2047487317712419
Singh, S., & Bittner, V. (2015). Familial hypercholesterolemia--epidemiology, diagnosis, and screening. Current Atherosclerosis Reports, 17(2), 482. https://doi.org/10.1007/s11883-014-0482-5
Strilchuk, L., Tocci, G., Fogacci, F., & Cicero, A. F. G. (2020). An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 21(5), 531–539. https://doi.org/10.1080/14656566.2020.1714028
Sturm, A. C., Knowles, J. W., Gidding, S. S., Ahmad, Z. S., Ahmed, C. D., Ballantyne, C. M., … Rader, D. J. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. Journal of the American College of Cardiology, 72(6), 662–680. https://doi.org/10.1016/j.jacc.2018.05.044
Turgeon, R. D., Barry, A. R., & Pearson, G. J. (2016). Familial hypercholesterolemia review of diagnosis, screening, and treatment. Canadian Family Physician, 62(1), 32–37.
Youngblom, E., Pariani, M., & Knowles, J. W. (2016). Familial Hypercholesterolemia. GeneReviews® [Internet], 1–28. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK174884/
Authors
Purwowiyoto, S. L. and Afiyani, N. . (2023) “Farmakoterapi Pasien Hiperkolesterolemia Familial: Suatu Tinjauan Narasi”, Farmasains : Jurnal Ilmiah Ilmu Kefarmasian, 10(1), pp. 9–18. doi: 10.22236/farmasains.v10i1.8743.
This work is licensed under a Creative Commons Attribution 4.0 International License.